ライフサイエンスコーパス: emetic

1 phamide regimens were reclassified as highly emetic.

2 and planned use of dexamethasone as an anti-emetic.

3 ive oral drug, praziquantel, replaced tartar emetic a s treatment f o r schistosomiasis in the entire

4 A is important for both the superantigen and emetic activities of this enterotoxin.

5 87A, and SEA-H187D retained superantigen and emetic activities, whereas SEA-H225A and SEA-H225D were

6 Histidine 61 appears to be important for emetic activity but not for superantigen activity, consi

7 son, SEA-H61A and SEA-H61D were defective in emetic activity but not in the ability to stimulate muri

8 stered in subcutaneous miniosmotic pumps and emetic activity in monkeys.

9 us miniosmotic pumps, but the protein lacked emetic activity.

10 s recommended in combination with other anti-emetic agents for the prevention of nausea and vomiting

11 s who receive this combination or any highly emetic agents should receive a 5-HT(3) receptor antagoni

12 nt of two types of food-borne disease, i.e., emetic and diarrheal syndrome.

13 s epilepticus had eluded recognition because emetic and other ictal autonomic manifestations were dis

14 oduced by Staphylococcus aureus that possess emetic and superantigenic properties.

15 ify the most appropriate cost-effective anti-emetics, and several trials recommending the addition of

16 onomic functions, including feeding and anti-emetic behaviours, when administered peripherally or int

17 ist and dexamethasone, were assigned to each emetic category.

18 sis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for n

19 2 mg) resulted in equivalent levels of total emetic control during the first 48 hours after chemother

20 monstrated a high level of satisfaction with emetic control, which was similar to reported results.

21 omiting is multimodal, with combination anti-emetics, dexamethasone, aggressive hydration, the avoida

22 eceptor antagonists; 2) whether an exogenous emetic dose of SP (50 mg/kg, i.p.) can penetrate into th

23 An emetic dose of SP selectively and rapidly penetrated the

24 A taste associated with emetic drugs produces conditioned disgust reactions in r

25 trast, the vomiting center mediates the anti-emetic effect of opioids.

26 zone, which is outside the BBB, mediates the emetic effect.

27 en suggested that morphine has dual effects; emetic effects and anti-emetic effects.

28 lopment of cisplatin's immediate and delayed emetic effects in the least shrew and subsequently deter

29 methiodide treatment virtually abolished the emetic effects of morphine.

30 e, which does not cross the BBB, antagonizes emetic effects of opioids.

31 mg/kg, i.p.) caused dose- and time-dependent emetic effects.

32 ne has dual effects; emetic effects and anti-emetic effects.

33 against pain of neuropathic origin) and anti-emetic effects.

34 Eleven patients (16.2%) had at least one emetic episode during the aprepitant cycle versus 32 pat

35 Secondary end points were emetic episodes (acute and delayed), nausea measurement

36 o rescue medication), major response (1 to 2 emetic episodes and no rescue medication), and patients'

37 cy criteria included complete response (zero emetic episodes and no rescue medication), major respons

38 Data from the latest survey showed zero emetic episodes in 93% and 87% of participants given mod

39 Most emetic episodes occurred during the initial phase of tre

40 ; P = .04), but not the mean number of acute emetic episodes or acute or delayed nausea severity comp

41 cannabinol (delta9-THC) is an effective anti-emetic; however, other potential gastrointestinal therap

42 nnabinol (Delta(9)-THC) is an effective anti-emetic; however, other potential gastrointestinal therap

43 A cathartic (sodium phosphate) and an emetic (ipecac) were given to all infected subjects and

44 and genotoxic, and does not seem to possess emetic-like side effects.

45 before X was paired with an injection of the emetic, lithium chloride.

46 concomitant changes in the turnover of major emetic neurotransmitters both in the central and periphe

47 l activity in the neurons of both brain stem emetic nuclei and the enteric nervous system of the gut;

48 ombining several therapies to block multiple emetic pathways should be attempted.

49 litarii, believed to be involved in terminal emetic pathways.

50 mesis model for both phases of CIV, and both emetic phases are associated with specific increases in

51 Preliminary studies have suggested that the emetic potency of PDE-IV inhibitors is correlated with a

52 in animal models of inflammation and reduced emetic potential compared to previously described drugs

53 sease-specific management teams assigned the emetic potential of chemotherapy programs to one of five

54 Efforts to eliminate the emetic potential of PDE-IV inhibitors were directed towa

55 preclinical inhaled PDE4 inhibitors with low emetic potential.

56 Consistent with their emetic properties once ingested, the compounds were high

57 ecommending the addition of steroids in anti-emetic prophylactic multimodal approaches.

58 ng knowledge of the neuropharmacology of the emetic reflex implicating glutamate, prostanoids, cannab

59 The neurocircuitry mediating the emetic reflex is still incompletely understood, and a ke

60 oratory species (e.g. rat and mouse) lack an emetic reflex, and the implications of this for models o

61 ion in the prevention of vasopressin-induced emetic response and gastric dysrhythmias.

62 gh doses, while SEA-H225A did not provoke an emetic response at low or high doses.

63 al of the SEs, purified SECcanine induces an emetic response in monkeys and the proliferation of T ce

64 SEA-H225D provoked an emetic response in monkeys only if fed at high doses, wh

65 t, rather than first assessing the patient's emetic response with less-effective treatment.

66 SEG and SEI elicited emetic responses in rhesus monkeys upon nasogastric admi

67 ong adult patients who are treated with high emetic risk antineoplastic agents.

68 ster antiemetics while considering patients' emetic risk categories and other characteristics.

69 Patients undergoing high emetic risk radiation therapy should receive a 5-HT(3) r

70 of palonosetron is recommended for moderate emetic risk regimens, combined with dexamethasone.

71 iving cisplatin and all other agents of high emetic risk, the two-drug combination of dexamethasone a

72 nts receiving other chemotherapy of moderate emetic risk, the Update Committee continues to recommend

73 For persons receiving chemotherapy of high emetic risk, there is no group of patients for whom agen

74 t is recommended before chemotherapy of high emetic risk.

75 emesis after chemotherapeutic agents of high emetic risk.

76 iemetic regimens for adults who receive high-emetic-risk antineoplastic agents or who experience brea

77 and for pediatric patients who receive high-emetic-risk antineoplastic agents.

78 cue therapy alone is now recommended for low-emetic-risk radiation therapy.

79 and demonstrated a significant reduction in emetic side effects (ferret, 20% emesis at 30 mg/kg, po)

80 ainst a wide range of peripheral and central emetic stimuli and clinical trials confirm that neurokin

81 amic variables after surgery, wake-up times, emetic symptoms, pain, and narcotic use were compared.

82 es were noted in recovery from anesthesia or emetic symptoms.

83 g food poisoning manifested by diarrhoeal or emetic syndromes.

84 e control campaigns using intravenous tartar emetic, the standard treatment for schistosomiasis, as c

85 -the legacy left from the mass use of tartar emetic to eradicate schistosomiasis, as in other high pr

86 lasmids from B. cereus isolates that produce emetic toxin or are linked to periodontal disease were s

87 The emetic toxin-producing isolate contained one approximate

88 evelopment of well tolerated cancer and anti-emetic treatments.

89 ) were given to all infected subjects and an emetic was given to 1 uninfected subject.